CA2654408C - Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance - Google Patents

Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance Download PDF

Info

Publication number
CA2654408C
CA2654408C CA2654408A CA2654408A CA2654408C CA 2654408 C CA2654408 C CA 2654408C CA 2654408 A CA2654408 A CA 2654408A CA 2654408 A CA2654408 A CA 2654408A CA 2654408 C CA2654408 C CA 2654408C
Authority
CA
Canada
Prior art keywords
subunit
antibodies
beta
insulin receptor
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2654408A
Other languages
English (en)
French (fr)
Other versions
CA2654408A1 (en
Inventor
Oleg Iliich Epshtein
Svetlana Alexandrovna Sergeeva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2006119658/15A external-priority patent/RU2437678C2/ru
Priority claimed from RU2006119655/15A external-priority patent/RU2438707C2/ru
Application filed by Individual filed Critical Individual
Publication of CA2654408A1 publication Critical patent/CA2654408A1/en
Application granted granted Critical
Publication of CA2654408C publication Critical patent/CA2654408C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA2654408A 2006-06-06 2007-05-31 Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance Expired - Fee Related CA2654408C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
RU2006119658 2006-06-06
RU2006119658/15A RU2437678C2 (ru) 2006-06-06 2006-06-06 Лекарственное средство для перорального лечения ожирения и способ получения твердой лекарственной формы для пероральной терапии ожирения
RU2006119655 2006-06-06
RU2006119655/15A RU2438707C2 (ru) 2006-06-06 2006-06-06 Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
PCT/RU2007/000288 WO2007149010A1 (en) 2006-06-06 2007-05-31 Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance

Publications (2)

Publication Number Publication Date
CA2654408A1 CA2654408A1 (en) 2007-12-27
CA2654408C true CA2654408C (en) 2018-05-08

Family

ID=38833657

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2654408A Expired - Fee Related CA2654408C (en) 2006-06-06 2007-05-31 Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance

Country Status (11)

Country Link
US (2) US9308259B2 (https=)
EP (2) EP2036574A4 (https=)
JP (1) JP5687425B2 (https=)
KR (1) KR20090024241A (https=)
AU (1) AU2007261782A1 (https=)
BR (1) BRPI0712540A2 (https=)
CA (1) CA2654408C (https=)
EA (1) EA200802440A1 (https=)
IL (2) IL195755A (https=)
MX (1) MX2008015621A (https=)
WO (1) WO2007149010A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
BRPI0712540A2 (pt) 2006-06-06 2012-10-16 Oleg Iliich Epshtein agente medicinal para tratar adiposidade, diabetes, e doenças associadas com intoleráncia a glicose
SG175077A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
EP2480888B1 (en) 2009-09-25 2016-11-30 XOMA Technology Ltd. Screening methods
PH12013500107A1 (en) 2010-07-15 2013-03-11 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
DE112011102350T5 (de) * 2010-07-15 2013-04-18 Oleg Iliich Epshtein Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Störungen des Urogenitalsystems
RU2610438C2 (ru) * 2011-06-02 2017-02-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ лечения патологического синдрома и лекарственное средство центрального и периферического действия для лечения патологического синдрома
EP2593477A2 (en) * 2010-07-15 2013-05-22 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment
EP2593474A2 (en) 2010-07-15 2013-05-22 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
PH12013500142A1 (en) * 2010-07-21 2013-03-11 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
KR20180127515A (ko) 2010-07-21 2018-11-28 올레그 일리치 엡쉬테인 당뇨병 및 대사성 장애의 치료를 위한 제약학적 복합 조성물 및 방법들
EA029199B1 (ru) 2010-07-21 2018-02-28 Олег Ильич Эпштейн Комбинированная фармацевтическая композиция для лечения синдрома дефицита внимания и гиперактивности и способы лечения синдрома дефицита внимания и гиперактивности
WO2012017328A2 (en) * 2010-08-06 2012-02-09 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
MX342034B (es) 2011-02-28 2016-09-12 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos.
AR085404A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas de union a antigeno
AU2012234282B2 (en) * 2011-03-28 2015-07-16 Ablynx Nv Method for producing solid formulations comprising immunoglobulin single variable domains
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
RU2603623C2 (ru) * 2014-06-06 2016-11-27 Олег Ильич Эпштейн Ветеринарная композиция и способ улучшения жизнеспособности животных, стимуляции прироста живой массы млекопитающих и птиц, повышения эффективности иммунизации, профилактики и/или лечения инфекционных заболеваний (варианты)
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
US12551526B2 (en) 2015-04-22 2026-02-17 Cedars-Sinai Medical Center Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes
CA2994841A1 (en) 2015-08-06 2017-02-09 Xoma (Us) Llc Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
WO2025171378A1 (en) 2024-02-09 2025-08-14 Rezolute, Inc. Insulin receptor modulation for tumor associated hyperinsulinism

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
JPS61176534A (ja) * 1985-01-30 1986-08-08 Takashi Muramatsu 避妊用剤
US4761371A (en) * 1985-02-12 1988-08-02 Genentech, Inc. Insulin receptor
US6803452B2 (en) 1991-02-26 2004-10-12 New York University RPTP-β antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
RU2007989C1 (ru) 1991-11-12 1994-02-28 Акционерное общество "Трейдис" Способ габович подбора гомеопатических препаратов и их разовой дозы
DK140992D0 (da) 1992-11-24 1992-11-24 Ole Buchardt Fremgangsmaade til frembringelse af antistoffer mod haptener og andre b-celle-antigener, antistoffer opnaaet ved fremgangsmaaden og anvendelse af disse antistoffer til fremstilling af vacciner, isaer til veterinaermedicinsk brug
US5879677A (en) 1992-12-09 1999-03-09 The Scripps Research Institute Method for inhibition of cerebral tissue factor mediated reperfusion damage
RU2033784C1 (ru) 1993-05-28 1995-04-30 Индивидуальное частное предприятие "Диалог" Устройство для репродуцирования гомеопатических и изопатических препаратов
IT1261849B (it) * 1993-09-02 1996-06-03 Avantgarde Spa Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
EP0652014A1 (en) 1993-11-10 1995-05-10 National Institute Of Immunology Treatment of prostatic hypertrophy
US5861266A (en) 1994-02-28 1999-01-19 New York University Treatment of diabetes mellitus and insulin receptor signal transduction
AU1812595A (en) 1994-02-28 1995-09-11 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Cell lines for the identification of substances affecting insulin receptor mediated signal transduction
IL110035A0 (en) 1994-06-16 1994-10-07 Tapuach Natural Technologies 1 Homeopathic formulations
RU2137483C1 (ru) 1995-08-02 1999-09-20 Божедомов Владимир Александрович Способ лечения урогенитальной хламидийной, уреаплазменной и микоплазменной инфекции
HUP9901890A3 (en) 1996-02-12 2001-04-28 Epshtein Oleg Iliich Medicament and method of treating an organism with medicaments
US5726027A (en) * 1996-03-08 1998-03-10 The Regents Of The University Of California Method for treatment of insulin resistance
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
RU2114646C1 (ru) 1996-09-30 1998-07-10 Олег Ильич Эпштейн Способ повышения защитных свойств организма при воздействии внешних физических факторов
RU2104032C1 (ru) 1997-03-11 1998-02-10 Общество с ограниченной ответственностью "Снежный барс" Способ усиления лечебного эффекта лекарственных средств
RU2122858C1 (ru) 1997-12-29 1998-12-10 Яковлева Людмила Борисовна Гомеопатическое лекарственное средство седативного действия "вернисон"
US6326360B1 (en) * 1998-03-11 2001-12-04 Grelan Pharmaceuticals Co., Ltd. Bubbling enteric coated preparations
RU2187334C2 (ru) 1998-05-22 2002-08-20 Эпштейн Олег Ильич Способ коррекции нарушенного иммунного гомеостаза и лекарственное средство
US6007824A (en) 1998-07-09 1999-12-28 Duckett; Melvin J. Natural composition and method for the treatment of sexual dysfunction
RU2144370C1 (ru) 1999-01-06 2000-01-20 Титиева Наталья Михайловна Гомеопатическое лекарственное средство для лечения гипертрофии предстательной железы
RU2161955C1 (ru) 1999-07-16 2001-01-20 Эпштейн Олег Ильич Способ изменения физико-химических или физико-химических и биологических свойств вещества
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
WO2002039923A2 (en) 2000-10-27 2002-05-23 Wayne State University Inhibition of alpha-2 hs glycoprotein (ahsg/fetuin) in obesity and insulin control of glucose homeostasis
RU2192882C1 (ru) 2001-04-18 2002-11-20 Эпштейн Олег Ильич Лекарственное средство и способ лечения патологического синдрома, обусловленного нарушением кроветворения
RU2199345C1 (ru) * 2001-12-26 2003-02-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции углеводного и жирового обмена
AUPS019802A0 (en) * 2002-01-31 2002-02-21 Chemstop Pty Ltd Nutrient formulation
UA76641C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
WO2004012765A1 (fr) 2002-08-02 2004-02-12 Oleg Iliich Epshtein Preparation medicinale et procede de traitement d'un syndrome pathologique determine par une perturbation de l'hematopoiese
UA76638C2 (en) * 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
RU2253478C1 (ru) * 2003-10-01 2005-06-10 Эпштейн Олег Ильич Средство для потенцирования лечебных эффектов - усиления действия лекарственного вещества
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
BRPI0712540A2 (pt) 2006-06-06 2012-10-16 Oleg Iliich Epshtein agente medicinal para tratar adiposidade, diabetes, e doenças associadas com intoleráncia a glicose
KR20180127515A (ko) * 2010-07-21 2018-11-28 올레그 일리치 엡쉬테인 당뇨병 및 대사성 장애의 치료를 위한 제약학적 복합 조성물 및 방법들

Also Published As

Publication number Publication date
EP2036574A1 (en) 2009-03-18
AU2007261782A1 (en) 2007-12-27
EA200802440A1 (ru) 2009-06-30
EP2036574A4 (en) 2009-07-01
US20110008452A1 (en) 2011-01-13
US20160159916A1 (en) 2016-06-09
CA2654408A1 (en) 2007-12-27
IL195755A0 (en) 2011-08-01
EP2395021A1 (en) 2011-12-14
MX2008015621A (es) 2009-03-06
BRPI0712540A2 (pt) 2012-10-16
JP2009539827A (ja) 2009-11-19
JP5687425B2 (ja) 2015-03-18
WO2007149010A1 (en) 2007-12-27
IL195755A (en) 2016-07-31
KR20090024241A (ko) 2009-03-06
US9308259B2 (en) 2016-04-12
IL246402A (en) 2017-12-31

Similar Documents

Publication Publication Date Title
CA2654408C (en) Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
AU2006340119B2 (en) Solid oral form of a medicinal preparation and a method for the production thereof
AU2011287292B2 (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
US20070141058A1 (en) Method of correcting immunopathological reactions and a medicament
SE1350212A1 (sv) Farmaceutisk kombinationskomposition och meto der för behandling av diabetes och metabola rubbningar
US7700096B2 (en) Medicinal agent for treating erectile dysfunction
US20120294899A1 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
CN101495143A (zh) 用于治疗肥胖、糖尿病和与受损的葡萄糖耐受性有关的疾病的药物制剂
CA2804969A1 (en) A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
RU2199345C1 (ru) Лекарственное средство и способ регуляции углеводного и жирового обмена
RU2437678C2 (ru) Лекарственное средство для перорального лечения ожирения и способ получения твердой лекарственной формы для пероральной терапии ожирения
RU2543332C2 (ru) Лекарственное средство для коррекции эндотелиальной дисфункции
RU2441023C1 (ru) Лекарственное средство для лечения рассеянного склероза и способ лечения рассеянного склероза
RU2531049C2 (ru) Лекарственное средство для лечения заболеваний предстательной железы и способ лечения заболеваний предстательной железы
RU2552221C2 (ru) Способ лечения ожирения и сопутствующих метаболических расстройств и лекарственное средство для лечения ожирения и сопутствующих метаболических расстройств
WO2015189709A2 (en) Veterinary composition and method of improving livability of animals, promoting live weight gain in mammals and birds, enhancing the effectiveness of immunization, and preventing and/or treating infectious diseases
CA2807529A1 (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220301

MKLA Lapsed

Effective date: 20200831